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Gastric cancer (GC) is one of the most common 
cancers worldwide. Among GC patients the mortality rate 
remains high - most are diagnosed at advanced disease 
stages due to the lack of symptoms in early disease. 
Prominent risk factors include age, male sex, smoking, 
radiation, H. pylori colonization, and a positive family 
history. Depending on tumor staging, treatment consists of 
neoadjuvant, adjuvant, and palliative therapy combining 
surgery and radiochemotherapy. 5-Fluorouracil, the 
first-line chemotherapeutic agent for metastatic GC, 
is ineffective in many patients, and methods to reliably 
distinguish patients that are resistant to 5-Fluorouracil-
based regimens, versus those that might benefit, are 
urgently warranted [1]. In the Vol.7, No.8 of Oncotarget, 
Li and colleagues describe a novel approach employing 
gene expression profiles to identify a prognostic molecular 
signature in GC patients. The authors identify and validate 
two gene-pairs (KCNE2 and API5, KCNE2 and PRPF3) 
that correlate with GC prognosis after 5-Fluorouracil 
chemotherapy [2]. The significance of this discovery 
comes more sharply into focus when one considers the 
already rich literature pertaining to the physiology and 
pathophysiology of KCNE2 in the gastric epithelium. 
KCNE2 is a relatively promiscuous, single 
transmembrane-spanning, voltage-gated potassium 
channel ancillary (β) subunit that is expressed in human 
heart but is also particularly enriched in certain secretory 
epithelia, including gastric parietal cells. In parietal cells, 
KCNE2 forms complexes with the KCNQ1 voltage-gated 
potassium channel pore-forming (α) subunit, resulting 
in a remarkable transformation. Homomeric KCNQ1 
channels are voltage-gated, i.e., activated by membrane 
depolarization, and are inhibited by low extracellular 
pH - not very helpful in the non-excitable parietal cell, 
which is exposed at its apical side to the low pH of the 
stomach lumen. However, KCNE2 converts KCNQ1 
to a potassium channel that is constitutively open over 
the range of membrane potentials exhibited by parietal 
cells. Furthermore, KCNQ1-KCNE2 channel activity is 
potentiated by extracellular protons. KCNQ1-KCNE2 
channels are thus able to function in non-excitable parietal 
cells, facing the acidic stomach lumen, and there they 
provide a K+ recycling pathway essential for function of 
the apical gastric H+/K+-ATPase that acidifies the stomach 
[3].
That KCNE2 is essential for parietal cell function 
is evidenced very well by findings from the Kcne2-/- 
mouse line. Kcne2 deletion essentially eliminates gastric 
acid secretion in mice, leaving their isolated parietal cells 
unresponsive to secretagogues and unable to secrete 
protons after proton loading. Kcne2-/- ex vivo mouse 
stomachs remain above pH 6.5 even when stimulated 
[4]. What happens as Kcne2-/- mice begin to age is just 
as striking, and highly pertinent to the recent findings 
of Li and colleagues [2]. By 12 months of age, Kcne2-
/- mouse stomachs reach six-fold their normal size 
because of hyperplasia, and the mice universally develop 
the preneoplastic condition, gastritis cystica profunda, 
in which large cysts develop associated with herniated 
glandular profiles in the gastric submucosa. Increased 
Ki67 and nuclear Cyclin D1 expression, together with 
TFF2- and cytokeratin 7-expressing metaplasia, are also 
present in the gastric mucosa of all Kcne2-/- mice of 
at least 1 year of age; some Kcne2-/- mice also exhibit 
pyloric polypoid adenomas and neoplastic invasion of 
blood vessels in the submucosa [5]. In addition to the 
findings from mice, KCNE2 protein expression was also 
shown to be downregulated in human gastric carcinoma 
and adenocarcinoma [5], and in both adenocarcinoma and 
at the edges of cysts in a patient who developed gastric 
adenocarcinoma subsequent to gastritis cystica profunda 
[6]. 
We do not yet fully understand the mechanisms 
underlying association of low KCNE2 expression 
with progression of GC. Chronic achlorhydria, as is 
caused by Kcne2 deletion in mice, can predispose to 
GC, therefore one might predict that this is a major 
part of the mechanism, at least in mice. However, in 
addition, KCNE2 may play other roles in cell cycling 
or proliferation. Tellingly, an earlier report identified 
KCNE2 as being downregulated in GC tissues and cell 
lines, and showed that KCNE2 overexpression effectively 
suppresses SGC7901 cell growth in soft agar and its 
tumorigenicity in nude mice, contexts in which gastric 
acidification is irrelevant [7]. One possibility is that loss 
of KCNE2 expression in GC contributes to aggressive 
growth of gastric tumors because of particularly extreme 
cell cycle dysregulation, enabling cells in these tumors 
to proliferate to the extent that they outpace the effects 
of 5-Fluorouracil, while not being technically resistant 
to 5-Fluorouracil. The idea of low KCNE2 expression 
being associated with hyperproliferation is also consistent 
with the fact that low KCNE2 expression is observed 
specifically at the edges of cysts in human gastritis cystica 
profunda [6]. Future work will elucidate whether KCNE2 
is a druggable target in GC and other cancers, in addition 
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to its promise as a stratification marker for 5-Fluorouracil 
responsiveness. In these efforts, it will be important 
to consider discoveries such as the value of KCNE2 as 
a prognostic marker, in the context of earlier work that 
already identified the link between KCNE2 and GC, and 
potential underlying mechanisms.
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